PrEP and Ireland: Availability, Effectiveness, and Concerns
WHO implementation tool for pre-exposure prophylaxis (PrEP) of HIV infection: module 6: pharmacists (Report). World Health Organization (WHO). July 2017. hdl:10665/258509. WHO/HIV/2017.27 License: CC BY-NC-SA 3.0 IGO.
Aloysius I, Savage A, Zdravkov J, Korologou-Linden R, Hill A, Smith R, Houghton-Price V, Boffito M, Nwokolo N. InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients. Journal of virus eradication. 2017 Oct 1;3(4):218-22.
Wang X, Nutland W, Brady M, Green I, Boffito M, McClure M. Quantification of tenofovir disoproxil fumarate and emtricitabine in generic pre-exposure prophylaxis tablets obtained from the internet. International journal of STD & AIDS. 2019 Jul;30(8):765-8.
Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink HJ, Rockstroh JK, Esser S. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016 Apr 1;44(2):151-8.
Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: a clinical practice guideline. https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Published March 2018.
Kojima N, Klausner JD. Is emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection safer than aspirin?. InOpen forum infectious diseases 2016 Jan 1 (Vol. 3, No. 1). Oxford University Press.
PrEP for Ireland – HIV Ireland [Internet]. Hivireland.ie. 2021 [cited 8 February 2021]. Available from: https://www.hivireland.ie/policy-news-and-media/our-policy-work/prep-for-ireland/
How to get PrEP [Internet]. sexualwellbeing.ie. 2021 [cited 8 February 2021]. Available from: https://www.sexualwellbeing.ie/sexual-health/prep/how-to-get-prep/
Lochlainn LN, O’Donnell K, Hurley C, Lyons F, Igoe D. Using data from a behavioural survey of men who have sex with men (MSM) to estimate the number likely to present for HIV pre-exposure prophylaxis (PrEP) in Ireland, 2017. Eurosurveillance. 2017 Nov 30;22(48):17-00768.
Hayes R, Schmidt AJ, Pharris A, Azad Y, Brown AE, Weatherburn P, Hickson F, Delpech V, Noori T. Estimating the ‘PrEP Gap’: how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019. Eurosurveillance. 2019 Oct 10;24(41):1900598.
Hilliard M. One in five are unaware of any HIV prevention methods, survey says [Internet]. The Irish Times. 2019 [cited 8 February 2021]. Available from: https://www.irishtimes.com/news/health/one-in-five-are-unaware-of-any-hiv-prevention-methods-survey-says-1
Donohoe K. PrEP Survey Finds High Awareness And Low Access Trends In Ireland [Internet]. GCN. 2018 [cited 8 February 2021]. Available from: https://gcn.ie/prep-survey-finds-high-awareness-low-access-trends/
Quirke S, Quinn L, Hegarty D, Loy A, Lyons F, Mulcahy F, Devitt E. Virtual HIV pre-exposure prophylaxis outpatient service in the era of COVID-19. International journal of STD & AIDS. 2020 Oct 13:0956462420961951.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine. 2010 Dec 30;363(27):2587-99.
McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet. 2016 Jan 2;387(10013):53-60.
Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015 Dec 3;373:2237-46.
Tetteh RA, Yankey BA, Nartey ET, Lartey M, Leufkens HG, Dodoo AN. Pre-exposure prophylaxis for HIV prevention: safety concerns. Drug safety. 2017 Apr 1;40(4):273-83.
Spinelli MA, Glidden DV, Anderson PL, Gandhi M, McMahan VM, Defechereux P, Schechter M, Veloso VG, Chariyalertsak S, Guanira JV, Bekker LG. Impact of estimated pre-exposure prophylaxis (PrEP) adherence patterns on bone mineral density in a large PrEP demonstration project. AIDS research and human retroviruses. 2019 Sep 1;35(9):788-93.
Pilkington V, Hill A, Hughes S, Nwokolo N, Pozniak A. How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. Journal of virus eradication. 2018 Oct 1;4(4):215-24.
Gandhi M, Glidden D, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A. Age, baseline kidney function, and medication exposure are associated with declines in creatinine clearance on PrEP: An observational cohort study. The lancet. HIV. 2016 Nov;3(11):e521.
Freeborn K, Portillo CJ. Does pre‐exposure prophylaxis for HIV prevention in men who have sex with men change risk behaviour? A systematic review. Journal of clinical nursing. 2018 Sep;27(17-18):3254-65.
Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, Stoové MA. Effects of pre-exposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis. Clinical Infectious Diseases. 2018 Aug 16;67(5):676-86.
Grant H, Mukandavire Z, Eakle R, Prudden H, B Gomez G, Rees H, Watts C. When are declines in condom use while using PrEP a concern? Modelling insights from a Hillbrow, South Africa case study. Journal of the International AIDS Society. 2017;20(1):21744.
Copyright (c) 2021 Thomas Ragonetti
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.